Maze Therapeutics, Inc.
MAZE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $698,547 | $698,243 | $698,243 |
| - Cash | $196,812 | $29,158 | $99,919 |
| + Debt | $26,628 | $49,623 | $32,055 |
| Enterprise Value | $528,363 | $718,708 | $630,379 |
| Revenue | $167,500 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $167,500 | $0 | $0 |
| % Margin | 100% | – | – |
| EBITDA | $60,883 | -$94,462 | -$107,206 |
| % Margin | 36.3% | – | – |
| Net Income | $52,231 | -$100,415 | -$114,940 |
| % Margin | 31.2% | – | – |
| EPS Diluted | 0.078 | -2.294 | -2.626 |
| % Growth | 103.4% | 12.6% | – |
| Operating Cash Flow | $75,954 | -$86,827 | -$99,203 |
| Capital Expenditures | -$1,147 | -$441 | -$1,966 |
| Free Cash Flow | $74,807 | -$87,268 | -$101,169 |